Printer Friendly

BIOMERICA AWARDED PATENT FOR NEW ALLERGY TREATMENT

 BIOMERICA AWARDED PATENT FOR NEW ALLERGY TREATMENT
 NEWPORT BEACH, Calif., June 11 /PRNewswire/ -- Biomerica Inc.


(NASDAQ: BMRA) has announced that it has just been issued a U.S. patent (No. 5,116,612) covering a new biomedical method for treating allergies. The patent deals with "Immunotherapy Agents for Treatment of IgE Mediated Allergies" and covers even a broader range than the Liposome patent (No. 5,049,390) issued to the company last September.
 The invention works by combining an allergen (the material to which a patient is allergic) and a Biological Response Modifier (BRM). This new medical approach has been found to be a highly effective immunotherapy agent.
 The coupling of allergens to the BRMs opens up a brand new field in therapeutic allergy. A large number of BRM agents including cytokines; bacterial, fungal and viral immunopotentiators; thymic factors; and others are disclosed as suitable BRMs for use in this invention.
 Examples of common allergens that may be linked to BRMs include milk, house dust, grass, pollen, shell fish, dog dander, cat dander and bee venom. Allergies effect more than 40 million individuals in the United States alone. Millions of these individuals receive allergy shots, called immunotherapy. The shots are a series of desensitization injections which are administered periodically for three to five years. Use of this new biomedical treatment method may dramatically shorten the time a patient must receive immunotherapy injections and hence offer more comfort and less expense.
 Biomerica intends to enter into a collaborative arrangement with a drug firm to utilize this invention. The company will also be working with medical doctors for an expansion of the allergy treatment program.
 Biomerica is a medical company engaged in the development, manufacturing and marketing of medical diagnostic products including home self-testing.
 -0- 6/11/92
 /CONTACT: Joseph Irani, president of Biomerica, 714-645-2111/
 (BMRA) CO: Biomerica Inc. ST: California IN: MTC SU:


KJ-EH -- LA002 -- 9090 06/11/92 08:52 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 11, 1992
Words:321
Previous Article:SPORT OF KINGS ANNOUNCES SCHEDULING OF LICENSING HEARINGS
Next Article:NEWBRIDGE SUPPLIES PRODUCTS FOR ECO 92 EARTH SUMMIT COMMUNICATIONS NETWORK IN BRAZIL
Topics:


Related Articles
BIOMERICA H. PYLORI TEST SALES SHOULD BENEFIT FROM NIH ANNOUNCEMENT
BIOMERICA H. PYLORI TEST SALES SHOULD BENEFIT FROM NIH ANNOUNCEMENT
Biomerica and Bentley Pharmaceuticals Reach Marketing and Distribution Agreement
Advanced Plant Pharmaceuticals Inc. - APPI - Chairman and Scientific Director Dr. Leonard Bielory Interviewed on NBC Nightly News and Quoted in New...
Biomerica to Produce Diagnostic Products For Worldwide Distribution by ICN Pharmaceuticals.
AVANIR Pharmaceuticals Identifies Small Molecule Found to Be Effective In Regulating the Causes of Allergy and Asthma.
Schering-Plough Announces FDA Approval of CLARINEX(R) (Desloratadine) for Treatment of Seasonal Allergic Rhinitis; New, Once-Daily, Nonsedating...
Sepracor Reports That Schering-Plough Announces FDA Approval of CLARINEX(R) (Desloratadine) for Treatment of Seasonal Allergic Rhinitis.
Schering-Plough Announces CLARINEX(R) (Desloratadine) Now Available Nationwide for Treatment of Seasonal Allergies; New Once-Daily, Nonsedating...
Barbara Bohle Awarded the WAO Henning LA[cedilla]wenstein Research Award 2007.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters